Method for inhibiting nano phospholipid disc penetrating through blood brain barrier and tau protein
By designing nano phospholipid disk carriers, using phospholipid self-assembly and targeted modification technology, the efficient penetration of the blood-brain barrier and accurate release of the drug is achieved, solving the problem of difficult to inhibit tau protein aggregation in the existing technology, and significantly improving Alz The treatment effect of Heimer's disease and other diseases.
Patent Information
- Application Number
- CN202411069805.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-15
AI Technical Summary
In neurodegenerative diseases such as Alzheimer's disease, existing drugs are difficult to effectively penetrate the blood-brain barrier, inhibit the aggregation of tau protein, resulting in poor treatment effect.
Design nano phospholipid disks as drug carriers to form a stable bilayer structure through phospholipid self-assembly, combine targeting and penetration modifications to penetrate the blood-brain barrier, and use environmentally sensitive or external stimulus-responsive materials to achieve accurate drug release and inhibit tau Aggregation of proteins.
It has achieved efficient penetration of the blood-brain barrier and precise delivery of drugs, significantly inhibited the aggregation of tau protein, improved the effectiveness of treating neurological diseases, and provided a new therapeutic strategy.
Smart Images

Figure CN118949072A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of molecular biotechnology, in particular to a method for inhibiting the penetration of a nano-phospholipid disk through a blood-brain barrier and tau protein. Background Art
[0002] Alzheimer's disease is a progressive neurodegenerative disease that occurs mostly in the elderly. The cause of the disease has not been clearly identified so far, and it is one of the most difficult medical problems facing clinical medicine.
[0004] In recent years, the repeated failures of early drug development targeting Aβ have led many drug developers to focus on tau protein. Compared with Aβ, the aggregation level of tau protein has a closer correlation with cognitive dysfunction. In view of this, we proposed a method for nanophospholipid disks to penetrate the blood-brain barrier and inhibit tau protein. Summary of the invention
[0005] The purpose of the present invention is to provide a method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein to solve the problems raised in the above-mentioned background technology.
[0006] To achieve the above object, the present invention provides the following technical solution: a method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein, comprising:
[0007] Nanophospholipid disc drug carrier design module: The nanophospholipid disc drug carrier design module uses phospholipid self-assembly to form a stable carrier, encapsulates drugs and introduces targeting and penetration modifications to achieve precise delivery;
[0008] Blood-brain barrier penetration and tau protein inhibition module: The blood-brain barrier penetration and tau protein inhibition module carries drugs through nanophospholipid disks, penetrates the blood-brain barrier, and delivers them to the brain in a targeted manner, inhibiting tau protein aggregation and treating neurological diseases;
[0009] Drug release control module: The drug release control module uses environmentally sensitive, degradable or external stimulus responsive materials to achieve precise drug release at a specific time and location, thereby improving the therapeutic effect;
[0010] Treatment effect evaluation and optimization module: The treatment effect evaluation and optimization module evaluates the efficacy and safety through in vitro and in vivo experiments, and optimizes the treatment plan based on the results to achieve the best treatment effect;
[0011] Wherein, the nanophospholipid disk drug carrier design module includes:
[0012] Preparation of nanophospholipid disk units
[0013] By utilizing the self-assembly characteristics of phospholipid molecules, nano-phospholipid disks with a stable phospholipid bilayer structure are formed under specific solvents and conditions. These phospholipid disks have a diameter of about 100 to 200 nm, which is similar to the structure of biological membranes and therefore has good biocompatibility. Commonly used phospholipid materials include dimyristoylphosphatidylcholine (DMPC) or palmitoyloleoylphosphatidylcholine (POPC), which have good stability and biodegradability.
[0014] Drug packaging unit
[0015] Mix drugs such as tau protein inhibitors with the phospholipid bilayer and encapsulate the drugs inside or on the surface of the phospholipid bilayer by physical or chemical methods. This process ensures the stability and biological activity of the drugs during delivery;
[0016] Phospholipid Modifiability Application Unit
[0017] By utilizing the modifiability of phospholipid molecules, specific functional groups or molecules, such as targeting ligands, membrane-penetrating peptides, etc., are introduced onto the surface of the phospholipid bilayer. These modified molecules can enhance the targeting and penetration ability of the nanophospholipid disks, making them more effective in penetrating the blood-brain barrier.
[0018] Preferably, the nanophospholipid disc drug carrier design module first selects phospholipid materials with good biocompatibility such as DPPC and POPC to ensure carrier stability, and secondly, adopts advanced packaging technology to improve drug encapsulation rate and stability and prevent drug leakage. Finally, by surface modification of specific ligands, precise targeted delivery of drugs to specific cells in the brain is achieved to improve the therapeutic effect.
[0019] Preferably, the blood-brain barrier penetration and tau protein inhibition module includes a blood-brain barrier penetration unit
[0020] Through the special surface modification (such as transmembrane peptide) and size advantage of nanophospholipid disks, it can penetrate the blood-brain barrier of mice. In this process, the nanophospholipid disks need to overcome the intercellular gaps and tight junctions of the blood-brain barrier to ensure that the drug can reach the target area of the brain.
[0021] Targeted delivery unit
[0022] The targeting ligands on the surface of the nanophospholipid disks can recognize and bind to tau proteins or related cells in the brain to achieve targeted drug delivery. This feature improves the bioavailability and therapeutic effect of the drug;
[0023] Tau Inhibitory Unit
[0024] When the nanolipid disks reach the target area of the brain, they release the drugs they carry, which bind to tau protein, inhibit its aggregation and phosphorylation process, and thus reduce tau protein-mediated neurotoxicity.
[0025] Preferably, in the drug delivery system, blood-brain barrier penetration and tau protein inhibition modules are crucial. We use specially designed nanophospholipid discs, which take advantage of their unique structure and surface modifications, such as transmembrane peptides, to effectively penetrate the blood-brain barrier. Once entering the brain, these carriers can accurately recognize and bind to tau protein, thereby inhibiting its abnormal aggregation and phosphorylation, and reducing neurotoxicity mediated by tau protein. The design of this module greatly improves the targeting and therapeutic effect of drugs in the brain, and provides a new strategy for the treatment of neurological diseases.
[0026] Preferably, the drug release control module comprises:
[0027] Responsive Release
[0028] Environmentally sensitive materials, such as pH-sensitive, temperature-sensitive or enzyme-sensitive materials, are used as part of or coatings of nanophospholipid disks. These materials undergo structural changes under specific environments (such as the acidic environment within diseased tissues, changes in body temperature or the presence of specific enzymes), leading to drug release.
[0029] Timed Release
[0030] Timed release of drugs is achieved by introducing degradable polymers or chemical bonds inside the nanophospholipid disks, which gradually degrade over a specific period of time, resulting in the release of drugs from the nanophospholipid disks;
[0031] External stimuli trigger release
[0032] External stimuli, such as light, magnetism, ultrasound, etc., are used to trigger the drug release from the nanophospholipid disks. This strategy allows researchers to remotely control the release of drugs through external devices when needed.
[0033] Preferably, the method for implementing the drug release regulation module includes:
[0034] Material selection
[0035] According to the needs of drug release regulation strategy, appropriate materials are selected to construct nanophospholipid disks, and these materials should have good biocompatibility, stability and controllability;
[0036] Drug encapsulation and introduction of regulatory molecules
[0037] In the drug encapsulation process, regulatory molecules (such as environmentally sensitive materials, degradable polymers or external stimulus responsive materials) are encapsulated together with the drugs inside or on the surface of the nanophospholipid disks. These regulatory molecules will control the release rate and pattern of the drug;
[0038] Drug release performance testing
[0039] In in vitro experiments, the drug release performance of nanophospholipid disks under different conditions was evaluated. The drug release rate and pattern were optimized by adjusting the type and concentration of regulatory molecules;
[0040] In vivo validation
[0041] The effectiveness and safety of the drug release control module were verified in the mouse model. The actual application effect of the drug release control module was evaluated by monitoring indicators such as drug biodistribution, metabolism and therapeutic effect.
[0042] Preferably, the material selection includes
[0043] Environmentally sensitive materials
[0044] pH-sensitive materials, such as polymethacrylic acid (PMAA), polystyrene sulfonic acid (PSSA), etc. These materials will be protonated in an acidic environment, resulting in structural changes, thereby triggering drug release. In a simulated physiological environment, such as the acidic environment in diseased tissue (pH about 6.5), these materials will responsively release drugs;
[0045] Temperature-sensitive materials, such as poly N-isopropylacrylamide (PNIPAM). PNIPAM has a lower critical solution temperature (LCST). When the temperature exceeds its LCST, a phase transition occurs, from hydrophilic to hydrophobic, thereby releasing the drug. In vivo, drug release can be triggered by external heating or heating of the lesion area;
[0046] Enzyme-sensitive materials, select certain enzyme-sensitive polysaccharides or peptides as coating materials. These materials will degrade under the action of specific enzymes, thereby releasing drugs. For example, hyaluronidase-sensitive materials will degrade under the action of hyaluronidase, and are suitable for releasing drugs in hyaluronidase-rich tumor microenvironments;
[0047] Degradable polymers
[0048] Polyesters, such as polylactic acid (PLA), polylactic acid-glycolic acid copolymer (PLGA), etc. These polymers have good biocompatibility and degradability. By controlling the molecular weight and degradation conditions of the polymer, the timed release of the drug can be achieved;
[0049] Polycarbonates, such as polytrimethylene carbonate (PTMC), etc. This type of material also has excellent biocompatibility and degradation, and can be adjusted as needed to achieve different drug release rates; external stimulus responsive materials
[0050] Light-sensitive materials, such as azobenzenes and spiropyrans. These materials undergo structural changes under light of a specific wavelength, thereby triggering drug release. By adjusting the intensity and wavelength of light, remote control of drug release can be achieved;
[0051] Magnetic sensitive materials, such as iron oxide nanoparticles, etc. These materials move or heat up under the influence of a magnetic field, thereby triggering drug release. Magnetic sensitive materials can achieve targeted positioning and timed release of drugs;
[0052] Ultrasound-sensitive materials, polymer nanoparticles, will break or deform under the action of ultrasound, thereby releasing drugs. This method can achieve non-invasive drug release control.
[0053] Preferably, the drug release control module is the key to ensure that the drug is released on demand in vivo. The module uses environmentally sensitive materials (such as pH sensitive materials), degradable polymers (such as PLGA) and external stimulus responsive materials (such as photosensitive materials) to achieve the timing and positioning release of drugs. These materials can respond to changes in the internal environment or external stimuli, thereby accurately controlling the release rate and pattern of the drug. In addition, by accurately controlling the release of drugs, the therapeutic effect can be improved and side effects can be reduced.
[0054] Preferably, the treatment effect evaluation and optimization module includes:
[0055] In vitro evaluation
[0056] Cytotoxicity test evaluates the toxicity of nanophospholipid disks and the drugs they carry in in vitro cell culture to ensure their safety during treatment.
[0057] Drug release kinetics, studying the drug release rate and pattern of nanophospholipid disks in an in vitro simulated environment to ensure that the drug can be fully released when it reaches the target area.
[0058] Targeting and penetration evaluation: The ability and targeting of nanophospholipid disks to cross the blood-brain barrier were evaluated by simulating the blood-brain barrier model in vitro.
[0059] In vivo evaluation
[0060] Pharmacokinetics and biodistribution, the metabolism, distribution and elimination of nanophospholipid disks and the drugs they carry in the body are studied in animal models to understand the behavior of drugs in the body.
[0061] Efficacy evaluation: The therapeutic effect of nanophospholipid disks in inhibiting tau protein and improving cognitive function is evaluated through animal models (such as AD model mice).
[0062] Safety assessment: monitor the physiological indicators and pathological changes of animal models during treatment, and evaluate the safety of nanophospholipid disks and the drugs they carry.
[0063] Treatment plan optimization
[0064] Dose optimization, based on the results of in vitro and in vivo experiments, optimize the administration dose of nanophospholipid disks to achieve the best therapeutic effect.
[0065] Optimize the route of administration, study the effects of different routes of administration (such as intravenous injection, nasal administration, etc.) on the therapeutic effect, and select the best route of administration.
[0066] Drug combination optimization, exploring the combined use of nanophospholipid disks with other drugs to exert synergistic effects and improve therapeutic effects.
[0067] Preferably, the treatment effect evaluation and optimization module focuses on accurately evaluating the efficacy of drugs and optimizing the treatment plan accordingly. First, the drug efficacy and safety are quantitatively evaluated through objective indicators such as blood biochemical indicators and imaging examinations. Secondly, the questionnaire survey method is used to collect patients' subjective feelings and evaluate the improvement of quality of life. In terms of optimization, individualized treatment strategies are emphasized, and the drug type, dosage and course of treatment are accurately adjusted according to individual differences such as patient age, gender, and condition. At the same time, by regularly monitoring the treatment effect and adjusting the treatment plan in time, patients can be ensured to obtain the best effect.
[0068] Compared with the prior art, the present invention provides a method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein, which has the following beneficial effects:
[0069] 1. The method for inhibiting the penetration of the blood-brain barrier and tau protein by the nanophospholipid disk. The stability of the phospholipid bilayer as the basic structure of the nanophospholipid disk ensures that the structural integrity can be maintained during the drug delivery process, thereby effectively penetrating the blood-brain barrier. Its size fixity ensures that it can maintain a constant size even when the phospholipid concentration changes. This feature not only helps to effectively encapsulate the drug, but also ensures that the drug will not leak during the delivery process due to changes in the size of the phospholipid layer, further enhancing the application potential of the nanophospholipid disk in delivering drugs across the blood-brain barrier.
[0070] 2. The method for inhibiting tau protein by penetrating the blood-brain barrier of the nanophospholipid disk. The modifiability of phospholipids provides great flexibility for the functionalization of the nanophospholipid disk. By introducing specific molecules or groups, the phospholipid surface can be precisely modified to achieve specific interaction with the blood-brain barrier or enhance targeting to specific cells. At the same time, regulating the proportion of internal functional phospholipids can precisely control the structure and properties of the nanophospholipid disk, such as fluidity and stability, thereby optimizing its performance in the drug delivery process and achieving more efficient and precise treatment.
[0071] 3. The method of inhibiting tau protein by the nanophospholipid disk through the blood-brain barrier. Due to its good biocompatibility, the nanophospholipid disk has demonstrated excellent secretion efficiency in cell and animal experiments. This drug carrier can efficiently deliver drugs to target cells while maintaining its stability in the body to avoid rapid clearance or degradation. This outstanding performance not only ensures that the drug can continue to exert its therapeutic effect, but also reduces side effects, providing an efficient and safe new way for drug delivery. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] Figure 1 Schematic diagram of the method for inhibiting the penetration of the blood-brain barrier and tau protein by the nanophospholipid disk of the present invention;
[0073] Figure 2 This is a schematic diagram of the design module of the nanophospholipid disk drug carrier of the present invention;
[0074] Figure 3 This is a schematic diagram of the blood-brain barrier penetration and tau protein inhibition module of the present invention;
[0075] Figure 4 This is a schematic diagram of the drug release control module of the present invention;
[0076] Figure 5 This is a schematic diagram of the drug release control module of the present invention;
[0077] Figure 6 A schematic diagram of material selection for the present invention;
[0078] Figure 7 This is a schematic diagram of the research route of the present invention;
[0079] Figure 8 It is intended to show the injection structure of the present invention. DETAILED DESCRIPTION
[0080] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0081] See also Figure 1-8 The present invention provides a technical solution: a method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein, comprising:
[0082] Nanophospholipid disc drug carrier design module: The nanophospholipid disc drug carrier design module uses phospholipid self-assembly to form a stable carrier, encapsulates drugs and introduces targeting and penetration modifications to achieve precise delivery;
[0083] Blood-brain barrier penetration and tau protein inhibition module: The blood-brain barrier penetration and tau protein inhibition module carries drugs through nanophospholipid disks, penetrates the blood-brain barrier, and delivers them to the brain in a targeted manner, inhibiting tau protein aggregation and treating neurological diseases;
[0084] Drug release control module: The drug release control module uses environmentally sensitive, degradable or external stimulus responsive materials to achieve precise drug release at a specific time and location, thereby improving the therapeutic effect;
[0085] Treatment effect evaluation and optimization module: The treatment effect evaluation and optimization module evaluates the efficacy and safety through in vitro and in vivo experiments, and optimizes the treatment plan based on the results to achieve the best treatment effect.
[0086] In one embodiment of the present invention, the nanophospholipid disk drug carrier design module includes:
[0087] Preparation of nanophospholipid disk units
[0088] By utilizing the self-assembly characteristics of phospholipid molecules, nano-phospholipid disks with a stable phospholipid bilayer structure are formed under specific solvents and conditions. These phospholipid disks have a diameter of about 100 to 200 nm, which is similar to the structure of biological membranes and therefore has good biocompatibility. Commonly used phospholipid materials include dimyristoylphosphatidylcholine (DMPC) or palmitoyloleoylphosphatidylcholine (POPC), which have good stability and biodegradability.
[0089] Drug packaging unit
[0090] Mix drugs such as tau protein inhibitors with the phospholipid bilayer and encapsulate the drugs inside or on the surface of the phospholipid bilayer by physical or chemical methods. This process ensures the stability and biological activity of the drugs during delivery;
[0091] Phospholipid Modifiability Application Unit
[0092] By utilizing the modifiability of phospholipid molecules, specific functional groups or molecules, such as targeting ligands, membrane-penetrating peptides, etc., are introduced onto the surface of the phospholipid bilayer. These modified molecules can enhance the targeting and penetration ability of the nanophospholipid disks, making them more effective in penetrating the blood-brain barrier.
[0093] The nanophospholipid disc drug carrier design module first selects phospholipid materials with good biocompatibility such as DPPC and POPC to ensure the stability of the carrier. Secondly, it adopts advanced packaging technology to improve the drug encapsulation rate and stability and prevent drug leakage. Finally, through surface modification of specific ligands, it achieves precise targeted delivery of drugs to specific cells in the brain and improves the therapeutic effect.
[0094] Blood-brain barrier penetration and tau protein inhibition module includes blood-brain barrier penetration unit
[0095] Through the special surface modification (such as transmembrane peptide) and size advantage of nanophospholipid disks, it can penetrate the blood-brain barrier of mice. In this process, the nanophospholipid disks need to overcome the intercellular gaps and tight junctions of the blood-brain barrier to ensure that the drug can reach the target area of the brain.
[0096] Targeted delivery unit
[0097] The targeting ligands on the surface of the nanophospholipid disks can recognize and bind to tau proteins or related cells in the brain to achieve targeted drug delivery. This feature improves the bioavailability and therapeutic effect of the drug;
[0098] Tau Inhibitory Unit
[0099] When the nanolipid disks reach the target area of the brain, they release the drugs they carry, which bind to tau protein, inhibit its aggregation and phosphorylation process, and thus reduce tau protein-mediated neurotoxicity.
[0100] In drug delivery systems, blood-brain barrier penetration and tau protein inhibition modules are crucial. We use specially designed nanophospholipid discs, which take advantage of their unique structure and surface modifications, such as transmembrane peptides, to effectively penetrate the blood-brain barrier. Once entering the brain, these carriers can accurately recognize and bind to tau protein, thereby inhibiting its abnormal aggregation and phosphorylation, and reducing neurotoxicity mediated by tau protein. The design of this module greatly improves the targeting and therapeutic effect of drugs in the brain, and provides a new strategy for the treatment of neurological diseases.
[0101] In one embodiment of the present invention, the drug release control module comprises:
[0102] Responsive Release
[0103] Environmentally sensitive materials, such as pH-sensitive, temperature-sensitive or enzyme-sensitive materials, are used as part of or coatings of nanophospholipid disks. These materials undergo structural changes under specific environments (such as the acidic environment within diseased tissues, changes in body temperature or the presence of specific enzymes), leading to drug release.
[0104] Timed Release
[0105] Timed release of drugs is achieved by introducing degradable polymers or chemical bonds inside the nanophospholipid disks, which gradually degrade over a specific period of time, resulting in the release of drugs from the nanophospholipid disks;
[0106] External stimuli trigger release
[0107] External stimuli, such as light, magnetism, ultrasound, etc., are used to trigger the drug release from the nanophospholipid disks. This strategy allows researchers to remotely control the release of drugs through external devices when needed.
[0108] The implementation method of the drug release control module includes:
[0109] Material selection
[0110] According to the needs of drug release regulation strategy, appropriate materials are selected to construct nanophospholipid disks, and these materials should have good biocompatibility, stability and controllability;
[0111] Drug encapsulation and introduction of regulatory molecules
[0112] In the drug encapsulation process, regulatory molecules (such as environmentally sensitive materials, degradable polymers or external stimulus responsive materials) are encapsulated together with the drugs inside or on the surface of the nanophospholipid disks. These regulatory molecules will control the release rate and pattern of the drug;
[0113] Drug release performance testing
[0114] In in vitro experiments, the drug release performance of nanophospholipid disks under different conditions was evaluated. The drug release rate and pattern were optimized by adjusting the type and concentration of regulatory molecules;
[0115] In vivo validation
[0116] The effectiveness and safety of the drug release control module were verified in the mouse model. The actual application effect of the drug release control module was evaluated by monitoring indicators such as drug biodistribution, metabolism and therapeutic effect.
[0117] Material options include
[0118] Environmentally sensitive materials
[0119] pH-sensitive materials, such as polymethacrylic acid (PMAA), polystyrene sulfonic acid (PSSA), etc. These materials will be protonated in an acidic environment, resulting in structural changes, thereby triggering drug release. In a simulated physiological environment, such as the acidic environment in diseased tissue (pH about 6.5), these materials will responsively release drugs;
[0120] Temperature-sensitive materials, such as poly N-isopropylacrylamide (PNIPAM). PNIPAM has a lower critical solution temperature (LCST). When the temperature exceeds its LCST, a phase transition occurs, from hydrophilic to hydrophobic, thereby releasing the drug. In vivo, drug release can be triggered by external heating or heating of the lesion area;
[0121] Enzyme-sensitive materials, select certain enzyme-sensitive polysaccharides or peptides as coating materials. These materials will degrade under the action of specific enzymes, thereby releasing drugs. For example, hyaluronidase-sensitive materials will degrade under the action of hyaluronidase, and are suitable for releasing drugs in hyaluronidase-rich tumor microenvironments;
[0122] Degradable polymers
[0123] Polyesters, such as polylactic acid (PLA), polylactic acid-glycolic acid copolymer (PLGA), etc. These polymers have good biocompatibility and degradability. By controlling the molecular weight and degradation conditions of the polymer, the timed release of the drug can be achieved;
[0124] Polycarbonates, such as polytrimethylene carbonate (PTMC), etc. This type of material also has excellent biocompatibility and degradation, and can be adjusted as needed to achieve different drug release rates; external stimulus responsive materials
[0125] Light-sensitive materials, such as azobenzenes and spiropyrans. These materials undergo structural changes under light of a specific wavelength, thereby triggering drug release. By adjusting the intensity and wavelength of light, remote control of drug release can be achieved;
[0126] Magnetic sensitive materials, such as iron oxide nanoparticles, etc. These materials move or heat up under the influence of a magnetic field, thereby triggering drug release. Magnetic sensitive materials can achieve targeted positioning and timed release of drugs;
[0127] Ultrasound-sensitive materials, polymer nanoparticles, will break or deform under the action of ultrasound, thereby releasing drugs. This method can achieve non-invasive drug release control.
[0128] The drug release control module is the key to ensure that the drug is released on demand in the body. This module uses environmentally sensitive materials (such as pH-sensitive materials), degradable polymers (such as PLGA), and external stimulus-responsive materials (such as photosensitive materials) to achieve timed and targeted drug release. These materials can respond to changes in the body environment or external stimuli to accurately control the release rate and pattern of the drug. In addition, by precisely controlling drug release, the therapeutic effect can be improved and side effects can be reduced.
[0129] In one embodiment of the present invention, the treatment effect evaluation and optimization module includes:
[0130] In vitro evaluation
[0131] Cytotoxicity test evaluates the toxicity of nanophospholipid disks and the drugs they carry in in vitro cell culture to ensure their safety during treatment.
[0132] Drug release kinetics, studying the drug release rate and pattern of nanophospholipid disks in an in vitro simulated environment to ensure that the drug can be fully released when it reaches the target area.
[0133] Targeting and penetration evaluation: The ability and targeting of nanophospholipid disks to cross the blood-brain barrier were evaluated by simulating the blood-brain barrier model in vitro.
[0134] In vivo evaluation
[0135] Pharmacokinetics and biodistribution, the metabolism, distribution and elimination of nanophospholipid disks and the drugs they carry in the body are studied in animal models to understand the behavior of drugs in the body.
[0136] Efficacy evaluation: The therapeutic effect of nanophospholipid disks in inhibiting tau protein and improving cognitive function is evaluated through animal models (such as AD model mice).
[0137] Safety assessment: monitor the physiological indicators and pathological changes of animal models during treatment, and evaluate the safety of nanophospholipid disks and the drugs they carry.
[0138] Treatment plan optimization
[0139] Dose optimization, based on the results of in vitro and in vivo experiments, optimize the administration dose of nanophospholipid disks to achieve the best therapeutic effect.
[0140] Optimize the route of administration, study the effects of different routes of administration (such as intravenous injection, nasal administration, etc.) on the therapeutic effect, and select the best route of administration.
[0141] Drug combination optimization, exploring the combined use of nanophospholipid disks with other drugs to exert synergistic effects and improve therapeutic effects.
[0142] The treatment effect evaluation and optimization module focuses on accurately evaluating the efficacy of drugs and optimizing the treatment plan accordingly. First, objective indicators such as blood biochemical indicators and imaging examinations are used to quantitatively evaluate the efficacy and safety of drugs. Second, questionnaire surveys are used to collect patients' subjective feelings and evaluate the improvement in quality of life. In terms of optimization, individualized treatment strategies are emphasized, and the type, dosage and course of treatment are accurately adjusted according to individual differences such as age, gender, and condition of patients. At the same time, by regularly monitoring the treatment effect and adjusting the treatment plan in a timely manner, patients can be ensured to obtain the best effect.
[0143] Working principle:
[0144] S1. Select appropriate phospholipid materials and drugs, prepare nanophospholipid disks by thin film dispersion method or solvent evaporation method, adjust the proportion of internal functional phospholipids to optimize the performance of nanophospholipid disks, and modify the phospholipid surface to enhance its targeting and ability to penetrate the blood-brain barrier.
[0145] S2. Encapsulate the drug inside the nanophospholipid disk to ensure the high encapsulation rate and stability of the drug, and verify the stability and drug release characteristics of the nanophospholipid disk encapsulating the drug in an in vitro environment.
[0146] S3. Select appropriate mouse strains to establish a neurodegenerative disease model associated with tau protein abnormalities, and monitor and evaluate the disease progression and symptom manifestations in mice.
[0147] S4. Deliver the drug-encapsulated nanophospholipid disks into mice through tail vein injection and other methods, and monitor the distribution of the nanophospholipid disks in the mice and the drug release.
[0148] S5. Regularly collect blood and brain tissue samples from mice to detect the level and aggregation of tau protein, and evaluate the improvement of the mice's neurological function through behavioral tests, pathological sections, and other methods.
[0149] S6. Monitor the general physiological indicators of mice, such as body weight, appetite, and activity, and evaluate the long-term safety and tolerability of the nanophospholipid disks in mice.
[0150] S7. Conduct statistical analysis on the experimental data and compare the treatment effects and safety differences between different groups.
[0151] Based on the experimental results, it was concluded that the application potential of nanophospholipid disks in penetrating the blood-brain barrier and inhibiting tau protein was evaluated.
[0152] The above generally describes the present invention in detail, but it is obvious to a person skilled in the art that some modifications or improvements can be made to the present invention. Therefore, modifications or improvements that do not depart from the spirit of the present invention are within the scope of protection of the present invention.
Claims
1. A method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein, characterized in that: include: Nanophospholipid disc drug carrier design module: The nanophospholipid disc drug carrier design module uses phospholipid self-assembly to form a stable carrier, encapsulates drugs and introduces targeting and penetration modifications to achieve precise delivery; Blood-brain barrier penetration and tau protein inhibition module: The blood-brain barrier penetration and tau protein inhibition module carries drugs through nanophospholipid disks, penetrates the blood-brain barrier, and delivers them to the brain in a targeted manner, inhibiting tau protein aggregation and treating neurological diseases; Drug release control module: The drug release control module uses environmentally sensitive, degradable or external stimulus responsive materials to achieve precise drug release at a specific time and location, thereby improving the therapeutic effect; Treatment effect evaluation and optimization module: The treatment effect evaluation and optimization module evaluates the efficacy and safety through in vitro and in vivo experiments, and optimizes the treatment plan based on the results to achieve the best treatment effect; Wherein, the nanophospholipid disk drug carrier design module includes: Preparation of nanophospholipid disk units By utilizing the self-assembly characteristics of phospholipid molecules, nano-phospholipid disks with a stable phospholipid bilayer structure are formed under specific solvents and conditions. These phospholipid disks have a diameter of about 100 to 200 nm, which is similar to the structure of biological membranes. Drug packaging unit Mixing drugs such as tau protein inhibitors with the phospholipid bilayer and encapsulating the drugs inside or on the surface of the phospholipid bilayer by physical or chemical methods; Phospholipid Modifiability Application Unit By utilizing the modifiability of phospholipid molecules, specific functional groups or molecules, such as targeting ligands, transmembrane peptides, etc., are introduced onto the surface of the phospholipid bilayer.
2. The method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein according to claim 1, characterized in that: The nanophospholipid disc drug carrier design module first selects phospholipid materials with good biocompatibility such as DPPC and POPC to ensure the stability of the carrier. Secondly, it adopts advanced packaging technology to improve the drug encapsulation rate and stability and prevent drug leakage. Finally, by modifying the surface with specific ligands, it achieves precise targeted delivery of drugs to specific cells in the brain and improves the therapeutic effect.
3. The method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein according to claim 1, characterized in that: The blood-brain barrier penetration and tau protein inhibition module includes: Blood-brain barrier penetrating unit The special surface modification (such as membrane-penetrating peptide) and size advantage of nanophospholipid disks enable them to penetrate the blood-brain barrier of mice; Targeted delivery unit The targeting ligands on the surface of the nanophospholipid disks can recognize and bind to tau proteins or related cells in the brain to achieve targeted drug delivery; Tau Inhibitory Unit When the nanophospholipid disks reach the target area of the brain, they release the drugs they carry.
4. The method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein according to claim 3, characterized in that: In the drug delivery system, blood-brain barrier penetration and tau protein inhibition modules are crucial. We use specially designed nanophospholipid disks and take advantage of their unique structure and surface modification.
5. The method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein according to claim 1, characterized in that: The drug release control module comprises: Responsive Release Environmentally sensitive materials, such as pH-sensitive, temperature-sensitive or enzyme-sensitive materials, are used as part of or coating the nanophospholipid disks, which can undergo structural changes under specific circumstances, leading to drug release. Timed Release Timed release of drugs is achieved by introducing degradable polymers or chemical bonds inside the nanophospholipid disks, which gradually degrade over a specific period of time, resulting in the release of drugs from the nanophospholipid disks; External stimuli trigger release External stimuli, such as light, magnetism, ultrasound, etc., are used to trigger the release of drugs from the nanophospholipid disks. This strategy allows researchers to remotely control the release of drugs through external devices when needed.
6. The method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein according to claim 5, characterized in that: The implementation method of the drug release control module includes: Material selection According to the needs of drug release regulation strategy, appropriate materials are selected to construct nanophospholipid disks. These materials should have good biocompatibility, stability and controllability. Drug encapsulation and introduction of regulatory molecules In the drug encapsulation process, the regulatory molecules are encapsulated together with the drugs inside or on the surface of the nanophospholipid disks; Drug release performance testing In in vitro experiments, the drug release performance of nanophospholipid disks under different conditions was evaluated, and the drug release rate and pattern were optimized by adjusting the type and concentration of regulatory molecules; In vivo validation The effectiveness and safety of the drug release regulation module were verified in a mouse model, and the actual application effect of the drug release regulation module was evaluated by monitoring indicators such as drug biodistribution, metabolism and therapeutic effect.
7. The method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein according to claim 1, characterized in that: The material selection includes Environmentally sensitive materials pH-sensitive materials, such as polymethacrylic acid (PMAA), polystyrene sulfonic acid (PSSA), etc. These materials will be protonated in an acidic environment, resulting in structural changes, thereby triggering drug release. In a simulated physiological environment, such as the acidic environment in diseased tissue (pH about 6.5), these materials will responsively release drugs; Temperature-sensitive materials, such as poly (N-isopropylacrylamide) (PNIPAM). PNIPAM has a lower critical solution temperature (LCST). When the temperature exceeds its LCST, a phase transition occurs from hydrophilic to hydrophobic, thereby releasing drugs. Enzyme-sensitive materials: some enzyme-sensitive polysaccharides or peptides are selected as coating materials. These materials will degrade under the action of specific enzymes, thereby releasing drugs; Degradable polymers Polyesters, such as polylactic acid (PLA), polylactic acid-glycolic acid copolymer (PLGA), etc. Polycarbonates, such as polytrimethylene carbonate (PTMC); External stimulus responsive materials Photosensitive materials, such as azobenzenes, spiropyrans, etc.; Magnetic sensitive materials, such as iron oxide nanoparticles; Ultrasound-sensitive materials, polymer nanoparticles will rupture or deform under the action of ultrasound, thereby releasing drugs.
8. The method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein according to claim 1, characterized in that: The drug release control module is the key to ensure the on-demand release of drugs in vivo. The module achieves timed and localized drug release by adopting environmentally sensitive materials (such as pH-sensitive materials), degradable polymers (such as PLGA) and external stimulus responsive materials (such as photosensitive materials).
9. The method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein according to claim 1, characterized in that: The treatment effect evaluation and optimization module includes: In vitro evaluation Cytotoxicity test evaluates the toxicity of nanophospholipid disks and the drugs they carry in in vitro cell culture to ensure their safety during treatment. Drug release kinetics, studying the drug release rate and pattern of nanophospholipid disks in an in vitro simulated environment to ensure that the drug can be fully released when it reaches the target area. Targeting and penetration evaluation: The ability and targeting of nanophospholipid disks to cross the blood-brain barrier were evaluated by simulating the blood-brain barrier model in vitro. In vivo evaluation Pharmacokinetics and biodistribution, the metabolism, distribution and elimination of nanophospholipid disks and the drugs they carry in the body are studied in animal models to understand the behavior of drugs in the body. Efficacy evaluation: The therapeutic effect of nanophospholipid disks in inhibiting tau protein and improving cognitive function is evaluated through animal models (such as AD model mice). Safety assessment: monitor the physiological indicators and pathological changes of animal models during treatment, and evaluate the safety of nanophospholipid disks and the drugs they carry. Treatment plan optimization Dose optimization, based on the results of in vitro and in vivo experiments, optimize the administration dose of nanophospholipid disks to achieve the best therapeutic effect. Optimize the route of administration, study the effects of different routes of administration (such as intravenous injection, nasal administration, etc.) on the therapeutic effect, and select the best route of administration. Drug combination optimization, exploring the combined use of nanophospholipid disks with other drugs to exert synergistic effects and improve therapeutic effects.
10. The method for inhibiting the penetration of nanophospholipid disks through the blood-brain barrier and tau protein according to claim 1, characterized in that: The treatment effect evaluation and optimization module focuses on accurately evaluating the efficacy of drugs and optimizing the treatment plan accordingly. First, the efficacy and safety of drugs are quantitatively evaluated through objective indicators such as blood biochemical indicators and imaging examinations. Secondly, questionnaire surveys are used to collect patients' subjective feelings and evaluate the improvement in quality of life. In terms of optimization, emphasis is placed on individualized treatment strategies, and the type, dosage and course of treatment of drugs are accurately adjusted according to individual differences such as age, gender, and condition of patients. At the same time, by regularly monitoring the treatment effects and adjusting the treatment plan in a timely manner, we ensure that patients receive the best therapeutic effect.
